血清胸苷激酶1对甲状腺癌诊断价值的meta分析

doi:10.3760/cma.j.issn.1007-1245.2022.03.015

国际医药卫生导报 ›› 2022, Vol. 28 ›› Issue (3): 357-360.DOI: 10.3760/cma.j.issn.1007-1245.2022.03.015

血清胸苷激酶1对甲状腺癌诊断价值的meta分析

刘慧轩何雅军

暨南大学附属广州红十字会医院检验科，广州　510220

收稿日期:2021-10-19 出版日期:2022-02-01 发布日期:2022-03-01
通讯作者: 何雅军，Email：heyajun0801@163.com

Meta-analysis of value of serum thymidine kinase 1 in diagnosis of thyroid cancer

Liu Huixuan, He Yajun

Clinical Laboratory, Guangzhou Red Cross Hospital, Jinan University, Guangzhou 510220, China

Received:2021-10-19 Online:2022-02-01 Published:2022-03-01
Contact: He Yajun, Email: heyajun0801@163.com

摘要/Abstract

摘要： 目的　探讨血清胸苷激酶1（serum thymidine kinase 1，S-TK1）在甲状腺癌诊断中的价值。方法　在PubMed、Web of Science、知网、维普、万方等数据库检索S-TK1诊断甲状腺癌的文献，检索年限从建库至2021年4月。应用MetaDiSc 1.4及RevMan 5.3进行meta分析。采用总受试者工作特征曲线平面图及Spearman相关系数评估阈值效应。异质性分析采用Cochrane-Q检验和I²检验。使用随机效应模型进行meta分析。结果　8篇文献符合纳入标准，其中甲状腺癌患者820例，正常或甲状腺良性肿瘤共831例。各研究之间存在异质性，按照随机效应模型计算，汇总灵敏度、特异度、阳性似然比、阴性似然比、受试者工作特征曲线下面积分别是73%（95%CI 0.70～0.76，601/820）、75%（95%CI 0.72～0.78，624/831）、3.63（95%CI 2.24～5.90）、0.34（95%CI 0.25～0.45）、0.84。结论　S-TK1诊断甲状腺癌的效能较好，有利于早期发现和诊断甲状腺癌，对甲状腺癌诊断有一定的临床指导意义。

关键词: 甲状腺癌, , 血清胸苷激酶1, meta分析

Abstract: Objective　To investigate the value of serum thymidine kinase 1 (S-TK1) in the diagnosis of thyroid cancer. Methods　The relevant literatures on S-TK1 in the diagnosis of thyroid cancer were searched and collected from PubMed, Web of Science, CNKI, VIP, Wanfang Database, and other databases from their establishment to April 2021. Meta-analysis was performed using Metadisc 1.4 and RevMan 5.3. Summary receiver operating characteristic curve plan and Spearman correlation coefficient were used to evaluate the threshold effect. Cochrane-Q test and I² test were used for heterogeneity analysis. The random effect model was used for meta-analysis. Results　Eight literatures met the inclusion criteria, including 820 cases of thyroid cancer and 831 cases normal or of benign thyroid tumors. Heterogeneity exists between the studies. The calculation based on the random effect model showed that the total sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, and summary receiver operating character curve area under curve were 73% (95%CI 0.70-0.76, 601/820), 75% (95%CI 0.72-0.78, 624/831), 3.63 (95%CI 2.24-5.90), 0.34 (95%CI 0.25-0.45), and 0.84, respectively. Conclusion　S-TK1 is effective in the diagnosis of thyroid cancer, which is beneficial to the early detection and diagnosis of thyroid cancer, and has certain clinical guiding significance in the diagnosis of thyroid cancer.

Key words: Thyroid cancer, Serum thymidine kinase 1, Meta-analysis

刘慧轩, 何雅军. 血清胸苷激酶1对甲状腺癌诊断价值的meta分析[J]. 国际医药卫生导报, 2022, 28(3): 357-360.

Liu Huixuan, He Yajun. Meta-analysis of value of serum thymidine kinase 1 in diagnosis of thyroid cancer[J]. International Medicine and Health Guidance News, 2022, 28(3): 357-360.

参考文献

[1] 董芬, 张彪, 单广良. 中国甲状腺癌的流行现状和影响因素[J]. 中国癌症杂志, 2016, 26(1): 47-52. DOI: 10.3969/j.issn.1007-3969.2016.01.008.

[2] Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies [J]. Ann Intern Med, 2011, 155(8): 529-536. DOI: 10.7326/0003-4819-155-8-201110180- 00009.

[3] 邬兰,张永,曾宪涛.QUADAS-2在诊断准确性研究的质量评价工具中的应用[J].湖北医药学院学报,2013,32(3):201-208. DOI:10.7543/j.issn.1006-9674.2013.03.004.

[4] 王永云,俞兰.血清胸苷激酶1在胃癌诊疗中的应用研究进展[J].国际医药卫生导报,2020,26(8):1037-1041. DOI: 10.3760/cma.j.issn.1007-1245.2020.08.001.

[5] 周国志, 曹秀峰, 朱斌, 等. 血清TK1的检测在甲状腺癌诊治中的临床意义[J]. 现代生物医学进展, 2012, 12(36): 7083-7085. DOI: 10.13241/j.cnki.pmb.2012.36.045.

[6] 李芳, 汪多平, 徐茂林, 等. 血清胸苷激酶检测在甲状腺良恶性疾病鉴别诊断中的应用价值[J]. 广西医科大学学报, 2015, 32(5): 728-730. DOI: 10.16190/j.cnki.45-1211/r.2015.05.010.

[7] 程田, 唐振林. TK1、TPOAb和TgAb对甲状腺结节良恶性的诊断价值[J]. 实用医学杂志, 2018, 34(22): 3764-3766. DOI: 10.3969/j.issn.1006-5725.2018.22.023.

[8] 汤承辉, 李学庆. 血清胸苷激酶1、甲状腺球蛋白和甲状腺转移因子1在甲状腺良、恶性结节中的诊断价值[J]. 临床荟萃, 2019, 34(2): 136-139. DOI:10.3969/j.issn.1004- 583X. 2019.02.009.

[9] 张军, 刘莉. 血清胸苷激酶1与甲状腺球蛋白抗体检测对甲状腺结节占位性病变的诊断价值[J]. 医学临床研究, 2019, 36(3): 517-518. DOI: 10.3969/j.issn.1671-7171.2019. 03.035.

[10] 高良, 罗文, 庞丽娜, 等. 彩色多普勒超声联合血清P53、midkine、S-TK1鉴别甲状腺结节良恶性的临床价值研究[J]. 现代生物医学进展, 2020, 20(19): 3655-3658. DOI: 10.13241/j.cnki.pmb.2020.19.010.

[11] 刘伟. 血清TK1、TSH、Tg、Anti-Tg联合检测对鉴别甲状腺结节良恶性的诊断价值[D]. 泸州: 西南医科大学, 2020. DOI: 10.27215/d.cnki.glzyu.2020.000157.

[12] 骆丽娅. 血清TK1、TPOAb、TgAb水平联合检测对甲状腺结节良恶性鉴别诊断效能的影响[J]. 黑龙江医药科学, 2020, 43(5): 111-112. DOI: 10.3969/j.issn.1008-0104. 2020.05.049.

血清胸苷激酶1对甲状腺癌诊断价值的meta分析

Meta-analysis of value of serum thymidine kinase 1 in diagnosis of thyroid cancer

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 3

编辑推荐

Metrics

[1]	刘斯平, 毛海燕. MSCT多期增强在结直肠癌术前TN分期中的价值分析及与病理分期对照研究[J]. 国际医药卫生导报, 2022, 28(4): 464-467.
[2]	潘春柳, 黄志华. ICU医用粘胶相关性皮肤损伤患者相关因素的meta分析[J]. 国际医药卫生导报, 2022, 28(2): 270-277.
[3]	渠吉皊, 沈易静, 侯苹, 周婷, 李永男, 冒鑫娥, 刘永兵. 白细胞介素-6与衰弱的相关性meta分析[J]. 国际医药卫生导报, 2021, 27(6): 802-806.